TP53 and neoplasm: Notably, both IKKα and IKKβ expression levels were downregulated under the exposure of arsenite and other tumor therapeutic agents (Figs. 1a, 8b, g), but only a reduction of IKKβ was triggered by p53-dependent transcriptional repression.